initial public offerings (IPOs) trading on American exchanges

Thursday, March 27, 2025

ADMA Biologics (ADMA)

ADMA Biologics makes human-derived immunoglobulin. Its products treat people whose bodies don't make enough antibodies to ward off illnesses from common viruses. Instead of risking illness, people with primary immunodeficiency receive regular infusions of ADMA's drugs.
  • Sector: Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 685
  • Founded by Adam S. Grossman and Jerrold B. Grossman in 2004  
  • Headquartered in Ramsey, New Jersey
  • https://www.admabiologics.com/
IPO: October 17, 2013







ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. 


ADMA's biggest moneymaker, Asceniv. 
ADMA Biologics developed Asceniv in-house. It's a cocktail created from super donors whose plasma has a high level of antibodies capable of handling respiratory syncytial virus, or RSV. RSV leads to cold symptoms in most people, but it can be serious in people with compromised immune systems.

Last year, Asceniv generated $216.7 million in sales. This year, it's expected to bring in $283 million, growing almost 31%. Earnings are also promising. In 2024, ADMA Biologics earned 49 cents per share, flipping from no earnings in the year-earlier period. This year, it's expected to notch a 71-cent profit, up 45%.

Asceniv accounts for slightly more than half of ADMA's total sales. The company also sells Bivigam and Nabi-HB, two products it acquired. Bivigam provides various antibodies found in a healthy immune system, while Nabi-HB protects against hepatitis B in people who've been exposed.
 

Monday, March 24, 2025

eToro Group (NASDAQ: ETOR) has filed for a proposed IPO

Digital investment platform eToro filed for an initial public offering, saying it applied to list on the Nasdaq Global Select Market under the symbol ETOR.

  • eToro’s net income grew to $192.4 million, compared with $15.3 million a year ago.
  • The company, founded in 2007, provides trading and an investment platform to its customers.

The company said Monday its platform allows users to trade equities, currencies and commodities. The platform also allows users to trade crypto assets, with the company's co-founder and chief executive, Yoni Assia, saying the platform has helped millions of investors access the asset class in a safe way.

Spark Capital II, BRM Group, Andalusian SPV III, SBT Venture Fund I and CM SPC are listed among the company's principal shareholders.

Earlier this month, the company said it recently completed a $250 million funding round at a valuation of $3.5 billion. Investors in the funding round included ION Group and SoftBank Vision Fund 2, the company said.

EToro didn't provide an expected size for its IPO, nor did it offer an expected price range.

The company was founded in 2007 and said as of Dec. 31, 2024, it had about 3.5 million funded accounts.

IPOs this week : March 24 - 28, 25 (wk 13)

CoreWeave – Livingston, N.J., 49 million shares, priced at $47-$55, managed by Morgan Stanley JP Morgan. Proposed Nasdaq symbol CRWV. Business: Provides cloud computing services with data centers optimized for AI workloads.

OMS Energy Technologies – Singapore, 5.6 million shares, priced at $8-$10, managed by Roth Cap.. Proposed Nasdaq symbol OMSE. Business: Singapore-based manufacturer of surface wellhead systems and oil country tubular goods.

Bgin Blockchain – Singapore, 6.3 million shares, priced at $7-$9, managed by Chardan Benchmark. Proposed Nasdaq symbol BGIN. Business: Makes equipment for cryptocurrency mining with a focus on alternative currencies.

Apimeds Pharmaceuticals – Hopewell, N.J., 4.5 million shares, priced at $4-$5, managed by D. Boral Capital. Proposed NYSE American symbol APUS. Business: Clinical stage biotech developing bee venom-based treatment for inflammation.

Vantage – Singapore, 3.3 million shares, priced at $4-$5, managed by Network 1. Proposed NYSE American symbol VNTG. Business: Singapore-based shipbroking company focused on petroleum products.

FatPipe – Salt Lake City, .7 million shares, priced at $5.75-$7.75, managed by D. Boral Capital. Proposed Nasdaq symbol FATN. Business: Provides network software solutions for enterprises.